MONO- OR DUAL-PHOSPHORYLATION OF AKT KINASE IS REGULATED BY DISTINCT RECEPTORS THAT INVOLVE THE COMMON INSULIN RECEPTOR SUBSTRATE

REFERENCES

• Alessi D. R., Andjelkovic M., Caudwell B., Cron P., Morrice N., Cohen P., Hemmings B. A. Mechanism of Activation of Protein Kinase B by Insulin and IGF–1. Embo J. 1996; 15: 6541–6551
   PubMed Web of Science ®Google Scholar
• Andjelkovic M., Maira S. M., Cron P., Parker P. J., Hemmings B. A. Domain Swapping Used to Investigate the Mechanism of Protein Kinase B Regulation by 3–Phosphoinositide-Dependent Protein Kinase 1 and Ser473 Kinase. Mol. Cell. Biol. 1999; 19: 5061–5072
   PubMedGoogle Scholar
• Araki E., Lipes M. A., Patti M. E., Bruning J. C., Haag B., Johnson R. S., Kahn C. R. Alternative Pathway of Insulin Signalling in Mice with Targeted Disruption of the. Nature. 1994; 372: 186–190
   PubMed Web of Science ®Google Scholar
• Bennett B. L., Cruz R., Lacson R. G., Manning A. M. Interleukin-4 Suppression of Tumor Necrosis Factor Alpha–Stimulated E–Selectin Gene Transcription is Mediated by STAT6 Antagonism of NF–kappaB. J. Biol. Chem. 1997; 272: 10212–10219
   PubMed Web of Science ®Google Scholar
• Bennett M. R., Evan G. I., Schwartz S. M. Apoptosis of Human Vascular Smooth Muscle Cells Derived from Normal Vessels and Coronary Atherosclerotic Plaques. J. Clin. Invest. 1995; 95: 2266–2274
   PubMed Web of Science ®Google Scholar
• Biedermann T., Mailhammer R., Mai A., Sander C., Ogilvie A., Brombacher F., Maier K., Levine A. D., Rocken M. Reversal of Established Delayed Type Hypersensitivity Reactions Following Therapy with IL–4 or Antigen–Specific Th2 Cells. Eur. J. Immunol. 2001; 31: 1582–1591
   PubMed Web of Science ®Google Scholar
• Cao X., Shores E. W., Hu-Li J., Anver M. R., Kelsall B. L., Russell S. M., Drago J., Noguchi M., Grinberg A., Bloom E. T. Defective Lymphoid Development in Mice Lacking Expression of the Common Cytokine Receptor Gamma Chain. Immunity. 1995; 2: 223–238, et al.
   PubMed Web of Science ®Google Scholar
• Cheng H. L., Steinway M., Delaney C. L., Franke T. F., Feldman E. L. IGF-I Promotes Schwann Cell Motility and Survival Via Activation of Akt. Mol. Cell Endocrinol. 2000; 170: 211–215
   PubMed Web of Science ®Google Scholar
• Chomarat P., Banchereau J. An Update on Interleukin-4 and its Receptor. Eur. Cytokine Netw. 1997; 8: 333–344
   PubMed Web of Science ®Google Scholar
• Cornacoff J. B., Gossett K. A., Barbolt T. A., Dean J. H. Preclinical Evaluation of Recombinant Human Interleukin–4. Toxicol. Lett. 1992; 299–310
   PubMedGoogle Scholar
• Demoulin J. B., Renauld J. C. Signalling by Cytokines Interacting with the Interleukin–2 Receptor Gamma Chain. Cytokines Cell Mol. Ther. 1998; 4: 243–256
   PubMedGoogle Scholar
• Ehret G. B., Reichenbach P., Schindler U., Horvath C. M., Fritz S., Nabholz M., Bucher P. DNA Binding Specificity of Different STAT Proteins. Comparison of In Vitro Specificity with Natural Target Sites. J. Biol. Chem. 2001; 276: 6675–6688
   PubMed Web of Science ®Google Scholar
• Fantin V. R., Keller S. R., Lienhard G. E., Wang L. M. Insulin Receptor Substrate 4 Supports Insulin–and Interleukin 4–Stimulated Proliferation of Hematopoietic Cells. Biochem. Biophys. Res. Commun. 1999; 260: 718–723
   PubMed Web of Science ®Google Scholar
• Feng N., Lugli S. M., Schnyder B., Gauchat J. F., Graber P., Schlagenhauf E., Schnarr B., Wiederkehr–Adam M., Duschl A., Heim M. H., Lutz R. A., Moser R. The Interleukin–4/Interleukin-13 Receptor of Human Synovial Fibroblasts: Overexpression of the Nonsignaling Interleukin–13 Receptor Alpha2. Lab. Invest. 1998; 78: 591–602
   PubMed Web of Science ®Google Scholar
• Feng N., Schnyder B., Vonderschmitt D. J., Ryffel B., Lutz R. A. Characterization of Interleukin–13 Receptor in Carcinoma Cell Lines and Human Blood Cells and Comparison with the Interleukin–4 Receptor. J. Recept. Signal Transduct. Res. 1995; 15: 931–949
   PubMedGoogle Scholar
• Flynn P., Wongdagger M., Zavar M., Dean N. M., Stokoe D. Inhibition of PDK–1 Activity Causes a Reduction in Cell Proliferation and Survival. Curr Biol. 2000; 10: 1439–1442
   PubMed Web of Science ®Google Scholar
• Hill M. M., Andjelkovic M., Brazil D. P., Ferrari S., Fabbro D., Hemmings B. A. Insulin-Stimulated Protein Kinase B Phosphorylation on Ser–473 is Independent of its Activity and Occurs Through a Staurosporine–Insensitive Kinase. J. Biol. Chem. 2001; 276: 25643–25646
   PubMed Web of Science ®Google Scholar
• Kaplan M. H., Daniel C., Schindler U., Grusby M. J. Stat Proteins Control Lymphocyte Proliferation by Regulating p27Kip1 Expression. Mol. Cell. Biol. 1998; 18: 1996–2003
   PubMed Web of Science ®Google Scholar
• Keegan A. D., Nelms K., White M., Wang L. M., Pierce J. H., Paul W. E. An IL–4 Receptor Region Containing an Insulin Receptor Motif is Important for IL–4-Mediated IRS–1 Phosphorylation and Cell Growth. Cell. 1994; 76: 811–820
   PubMed Web of Science ®Google Scholar
• Lahm H., Amstad P., Yilmaz A., Borbenyi Z., Wyniger J., Fischer J. R., Suardet L., Givel J. C., Odartchenko N. Interleukin 4 Down–Regulates Expression of c–Kit and Autocrine Stem Cell Factor in Human Colorectal Carcinoma Cells. Cell Growth Differ. 1995; 6: 1111–1118
   PubMedGoogle Scholar
• Lahm H., Amstad P., Yilmaz A., Fischer J. R., Givel J. C., Odartchenko N., Sordat B. Differential Effect of Interleukin–4 and Transforming Growth Factor Beta 1 on Expression of Proto–Oncogenes and Autocrine Insulin–Like Growth Factor II in Colorectal Carcinoma Cells. Biochem. Biophys. Res. Commun. 1996; 220: 334–340
   PubMedGoogle Scholar
• Lahm H., Schnyder B., Wyniger J., Borbenyi Z., Yilmaz A., Car B. D., Fischer J. R., Givel J. C., Ryffel B. Growth Inhibition of Human Colorectal–Carcinoma Cells by Interleukin–4 and Expression of Functional Interleukin–4 Receptors. Int. J. Cancer. 1994; 59: 440–447
   PubMed Web of Science ®Google Scholar
• Miles P. D., Romeo O. M., Higo K., Cohen A., Rafaat K., Olefsky J. M. TNF-Alpha-Induced Insulin Resistance In Vivo and its Prevention by Troglitazone. Diabetes. 1997; 46: 1678–1683
   PubMed Web of Science ®Google Scholar
• Morelon E., Dautry-Varsat A., Le Deist F., Hacein-Bay S., Fischer A., de Saint Basile G. T-Lymphocyte Differentiation and Proliferation in the Absence of the Cytoplasmic Tail of the Common Cytokine Receptor Gamma C Chain in a Severe Combined Immune Deficiency X1 Patient. Blood 1996; 88: 1708–1717
   PubMedGoogle Scholar
• Russell S. M., Johnston J. A., Noguchi M., Kawamura M., Bacon C. M., Friedmann M., Berg M., McVicar D. W., Witthuhn B. A., Silvennoinen O. Interaction of IL–2R Beta and Gamma C Chains with Jak1 and Jak3: Implications for XSCID and XCID. Science. 1994; 266: 1042–1045, et al.
   PubMed Web of Science ®Google Scholar
• Russell S. M., Keegan A. D., Harada N., Nakamura Y., Noguchi M., Leland P., Friedmann M. C., Miyajima A., Puri R. K., Paul W. E. Interleukin-2 Receptor Gamma Chain: A Functional Component of the Interleukin–4 Receptor. Science 1993; 262: 1880–1883, et al.
   PubMed Web of Science ®Google Scholar
• Scheid M. P., Duronio V. Dissociation of Cytokine–Induced Phosphorylation of Bad and Activation of PKB/akt: Involvement of MEK Upstream of Bad Phosphorylation. Proc. Natl. Acad. Sci. USA 1998; 95: 7439–7444
   PubMed Web of Science ®Google Scholar
• Schnyder B., Lahm H., Woerly G., Odartchenko N., Ryffel B., Car B. D. Growth Inhibition Signalled Through the Interleukin–4/Interleukin-13 Receptor Complex is Associated with Tyrosine Phosphorylation of Insulin Receptor Substrate–1. Biochem. J. 1996b; 315: 767–774
   PubMed Web of Science ®Google Scholar
• Schnyder B., Lugli S., Feng N., Etter H., Lutz R. A., Ryffel B., Sugamura K., Wunderli-Allenspach H., Moser R. Interleukin-4 (IL-4) and IL–13 Bind to a Shared Heterodimeric Complex on Endothelial Cells Mediating Vascular Cell Adhesion Molecule–1 Induction in the Absence of the Common Gamma Chain. Blood 1996a; 87: 4286–4295
   PubMed Web of Science ®Google Scholar
• Schnyder B., Lugli S. M., Schnyder-Candrian S., Eng V. M., Moser R., Banchereau J., Ryffel B., Car B. D. Biochemical and Morphological Characterization of Vascular and Lymphocytic Interleukin–4 Receptors. Am. J. Pathol. 1996c; 149: 1369–1379
   PubMedGoogle Scholar
• Shimoda K., van Deursen J., Sangster M. Y., Sarawar S. R., Carson R. T., Tripp R. A., Chu C., Quelle F. W., Nosaka T., Vignali D. A., Doherty P. C., Grosveld G., Paul W. E., Ihle J. N. Lack of IL–4-Induced Th2 Response and IgE Class Switching in Mice with Disrupted Stat6 Gene. Nature. 1996; 380: 630–633
   PubMed Web of Science ®Google Scholar
• Wright K., Kolios G., Westwick J., Ward S. G. Cytokine-Induced Apoptosis in Epithelial HT–29 Cells is Independent of Nitric Oxide Formation. Evidence for an Interleukin–13-Driven Phosphatidylinositol 3–Kinase-Dependent Survival Mechanism. J. Biol. Chem. 1999; 274: 17193–17201
   PubMed Web of Science ®Google Scholar
• Zamorano J., Wang H. Y., Wang L. M., Pierce J. H., Keegan A. D. IL-4 Protects Cells from Apoptosis Via the Insulin Receptor Substrate Pathway and a Second Independent Signaling Pathway. J. Immunol. 1996; 157: 4926–4934
   PubMedGoogle Scholar
• Zurawski G., de Vries J. E. Interleukin 13, an Interleukin 4–Like Cytokine that Acts on Monocytes and B Cells, but not on T Cells. Immunol. Today. 1994; 15: 19–26
   PubMedGoogle Scholar
• Munson P. J., Rodbard D. LIGAND: A Versitile Computerized Approach for Characterization of Ligand–Binding Systems. Anal. Biochem. 1980; 107: 220–239
   PubMed Web of Science ®Google Scholar